Retrospective cohort study developed a risk score for predicting venous thromboembolism in lung cancer patients, suggesting clinical utility for risk stratification.
Key Points
The score stratifies patients into low, moderate, and high risk for venous thromboembolism, aiding early intervention.
Incidence of venous thromboembolism was 26.8% in the development group, demonstrating significant prevalence in lung cancer patients.
Assessment involved 401 lung cancer patients over a decade, applying univariate and multivariate analyses to develop the risk score.
Moderate predictive power was maintained in validation tests, underscoring the need for further nationwide prospective studies.